Cell/Gene Tx channel feed

CRISPR Ther­a­peu­tics gets a snap­shot of off-the-shelf CAR-T suc­cess in B-cell ma­lig­nan­cies — marred by the death of a pa­tient

5 years ago
R&D

Spar­ingVi­sion rais­es $52M to kick off long jour­ney for a next-gen gene ther­a­py that goes much, much broad­er than Lux­tur­na

5 years ago
Financing

CAR-plus: Irish biotech re­cruits Kite alum Chris Now­ers to prep dual-tar­get­ing NK cell ther­a­py for the clin­ic

5 years ago
Financing

FDA of­fi­cials, ex­perts dis­cuss im­pact of Covid-19 on cell and gene ther­a­pies

5 years ago
FDA+
Coronavirus

Pa­tient death in piv­otal gene ther­a­py tri­al rat­tles Sarep­ta part­ner al­ready fac­ing clin­i­cal hold

5 years ago
R&D

Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline

5 years ago
Deals

Out to pi­o­neer gene edit­ing in Chi­na, Edi­Gene bags $67M to be­gin clin­i­cal test­ing for β-tha­lassemia ther­a­py, uni­ver­sal CAR-T

5 years ago
Financing
China

Voy­ager shares take a hit as FDA slaps a hold on the IND for Hunt­ing­ton's gene ther­a­py — their #2 play in the pipeline

5 years ago
FDA+

A2 Bio­ther­a­peu­tics nabs $71M-plus Se­ries B for se­lec­tive cell ther­a­py pipeline

5 years ago
Financing

Io­vance shares ham­mered on TIL ther­a­py fil­ing de­lay — al­though an­a­lysts aren't as both­ered

5 years ago

FDA gives thumbs down for Mesoblast's aGVHD drug, say­ing one sin­gle-arm tri­al is not enough

5 years ago
FDA+

Mesoblast asks for trad­ing halt as PDU­FA date slides by. What's up?

5 years ago
FDA+

Sol­id gets an­oth­er shot in DMD gene ther­a­py race as FDA lifts hold. But is it too late to catch Pfiz­er, Sarep­ta?

5 years ago
R&D
FDA+

Still held down by clin­i­cal hold, No­var­tis' Zol­gens­ma falls fur­ther be­hind Bio­gen and Roche as FDA asks for a new piv­otal study

5 years ago
FDA+

Scoop: ARCH’s Bob Nelsen is back­ing an mR­NA up­start that promis­es to up­end the en­tire man­u­fac­tur­ing side of the glob­al busi­ness

5 years ago
Outsourcing

Can a mag­net­ic cell ther­a­py re­place corneal trans­plan­ta­tion? As eight-year jour­ney leads to the clin­ic, two broth­ers un­veil bold vi­sion

5 years ago
Startups

Af­ter bruis­ing re­jec­tion, blue­bird and Bris­tol My­ers Squibb land ide-cel pri­or­i­ty re­view. But will it mat­ter for the CVR?

5 years ago
R&D

Rocked by cus­toms in­ves­ti­ga­tion, Leg­end's CFO takes over as CEO Frank Zhang placed un­der house ar­rest

5 years ago
People
China

#ES­MO20: Au­to­lus pro­vides glimpse of next-gen­er­a­tion CAR-T pro­gram, show­ing ear­ly pos­i­tive safe­ty da­ta

5 years ago
R&D

A long­time Cy­tomX ex­ec re-emerges at Syn­thekine, an $82M Stan­ford spin­out

5 years ago
People
Financing

Sarep­ta faces an­oth­er gene ther­a­py hic­cup as Re­genxbio sues over Jim Wilson's patent

5 years ago

Mod­er­na picks up a $75M cash wind­fall as long­time col­lab­o­ra­tor Ver­tex signs up for a gene edit­ing as­sault on cys­tic fi­bro­sis

5 years ago
Deals

Ver­sant teams up with Stan­ford gene edit­ing ex­perts on a $45M next-gen play — mar­ry­ing CRISPR and AAV to fix sick­le cell

5 years ago
Financing
Startups

Take­da opens cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty — tucked right in its Boston R&D hub

5 years ago
First page Previous page 43444546474849 Next page Last page
A service from the Financial Times